Ovarian cancer

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

Retrieved on: 
Tuesday, January 9, 2024

Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.

Key Points: 
  • Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.
  • The entire medical research fraternity has prioritized cancer research in order to find new ways of treatment and analysis.
  • According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
  • The article continued: “Drugs such as morphine, fentanyl, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and others are used extensively in treating cancer pain in patients with lung cancer, bone cancer, and other types of cancer.

Utah Fertility Center, an Ivy Fertility Clinic, Hires Dr. C. Matthew Peterson

Retrieved on: 
Friday, January 12, 2024

Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed C. Matthew Peterson, MD, to its team of physicians at Utah Fertility Center.

Key Points: 
  • Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed C. Matthew Peterson, MD, to its team of physicians at Utah Fertility Center.
  • Dr. Peterson is a board certified reproductive endocrinologist and infertility specialist.
  • “We are thrilled to welcome Dr. Peterson to Utah Fertility Center,” said Dierdre Conway, MD, practice director at Utah Fertility Center.
  • “I look forward to working alongside the compassionate individuals at Utah Fertility Center and Ivy Fertility,” said Dr. Peterson.

RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

Retrieved on: 
Friday, January 12, 2024

This marks another significant development following the FDA's approval to RC88's international multicenter Phase II clinical trials last month.

Key Points: 
  • This marks another significant development following the FDA's approval to RC88's international multicenter Phase II clinical trials last month.
  • RC88 consists of a recombinant humanized anti-MSLN monoclonal antibody linked to the microtubule inhibitor monomethyl auristatin E (MMAE), which acts as a microtubule inhibitor.
  • The later the stage and the more aggressive the ovarian cancer, the higher the expression rate of MSLN, and current treatment options are limited.
  • Moving forward, RemeGen will continue to accelerate the development of its ADC products, with the aim of bringing more and better solutions to patients globally."

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Retrieved on: 
Monday, January 8, 2024

This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics.

Key Points: 
  • This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics.
  • The platform includes a rich biomarker portfolio addressing a wide range of high-priority health concerns beyond oncology, extending into areas of substantial medical need.
  • Highlights from the asset portfolio include:
    The Mitomic Endometriosis Test (MET™) is in development as a blood-based assay for diagnosis of endometriosis.
  • The overarching goal is to enhance clinical outcomes by offering non-invasive or minimally invasive testing at the early stages of disease progression.

Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024

Incyte (Nasdaq:INCY) will highlight growth opportunities and provide key updates across its investigational pipeline and commercial portfolio during a presentation today at 7:30 a.m. PT at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Key Points: 
  • Incyte (Nasdaq:INCY) will highlight growth opportunities and provide key updates across its investigational pipeline and commercial portfolio during a presentation today at 7:30 a.m. PT at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
  • The overall safety profile of ruxolitinib cream is consistent with previous data, and no new safety signals were observed.
  • The Company intends to provide additional financial guidance and updates on key clinical programs during its 2023 fourth quarter and year-end earnings conference call.
  • The J.P. Morgan Healthcare Conference presentation and Q&A session can be accessed at investor.incyte.com .

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

Retrieved on: 
Monday, January 8, 2024

AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2024.

Key Points: 
  • AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2024.
  • “In 2023, we delivered key safety and efficacy data across our clinical development program for SL-172154 and further strengthened our financial resources, which we believe will carry us beyond upcoming milestones in the year ahead,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck Labs.
  • On December 21, 2023, Shattuck announced a $50 million registered offering of common stock and concurrent private placement of pre-funded warrants.
  • Initial combination data from the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected mid-year 2024.

ProfoundBio Announces Rinatabart Sesutecan FDA Fast Track Designation for Patients with Advanced Ovarian Cancer

Retrieved on: 
Friday, January 5, 2024

SEATTLE, Jan. 5, 2024 /PRNewswire/ -- ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rinatabart sesutecan (Rina-S; PRO1184), a folate receptor alpha (FRα) targeted ADC, for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Key Points: 
  • SEATTLE, Jan. 5, 2024 /PRNewswire/ -- ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rinatabart sesutecan (Rina-S; PRO1184), a folate receptor alpha (FRα) targeted ADC, for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.
  • Fast Track designation is intended to facilitate the development and expedited review of drugs with demonstrated potential to improve over available therapy for serious conditions with unmet medical need.
  • "Our receipt of Fast Track designation from the FDA underscores our belief in the tremendous promise of Rina-S as a potential best-in-class FRα ADC to address the significant need for improved treatment options for advanced ovarian cancer," said Naomi Hunder, Chief Medical Officer of ProfoundBio.
  • "FRα is a highly prevalent antigen in ovarian cancer and Rina-S has shown encouraging antitumor activity and tolerability in our Phase 1 dose escalation study in ovarian and endometrial cancer patients across the full spectrum of FRα expression.

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Retrieved on: 
Thursday, January 4, 2024

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting an investor webcast today highlighting the significant potential of luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC. The presentation will include an overview of the clinical data supporting luvelta’s broad opportunity to address the unmet need in several FolRα-expressing cancers, including platinum-resistant ovarian cancer (PROC), endometrial cancer, CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), and non-small cell lung cancer (NSCLC).

Key Points: 
  • “Luvelta has been studied in over 180 patients to-date, and has demonstrated both promising clinical activity and a tolerable safety profile.
  • We are optimistic about its potential to change the cancer treatment landscape,” said Bill Newell, Sutro’s Chief Executive Officer.
  • “This includes the potential to be the first ADC to treat ovarian cancer patients with low to medium FolRα expression, which could double the current eligible patient population relative to the FolRα-targeting ADC on the market.
  • Sutro management and Dr. Monk will participate in a Q&A session at the end of the presentation.